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Abstract: A 31-year-old man had been treated with carbamazepine (CBZ) for 6 years and 
warfarin with bucolome for 2 years before developing hyponatremia 7 days after an injection 
of interferon-alpha 2b and starting oral ribavirin for chronic hepatitis C virus infection. Despite 
the hyponatremia, urinary osmolality exceeded plasma osmolality, and urinary excretion 
volume decreased markedly after water loading. Restriction of water intake and administration 
of dimethylchlortetracycline improved the hyponatremia, and lithium therapy maintained 
the normonatremia for one year. The hyponatremia recovered 6 months after the interferon-
alpha 2b therapy was completely stopped. In the present case, the syndrome of inappropriate 
antidiuresis may have been caused by the effect of interferon-alpha 2b on the renal distal tubules 
that had been sensitized by CBZ. Patients on CBZ therapy should be carefully observed for the 
development of hyponatremia when they are started on interferon-alpha 2b injections.
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Introduction
Carbamazepine (CBZ), a commonly prescribed medication in psychiatry and 
neurology, produces side effects with an incidence ranging from 33%–50%. 
CBZ-induced hyponatremia is a well-described side effect, and numerous studies 
have shown that age, hyponatremia dosage/level, and polypharmacy are predisposing 
risk factors for CBZ-induced hyponatremia (Gandelman 1994). Polypharmacy is a 
particularly important risk factor (Kuz and Manssourian 2005).
We report a case of the syndrome of inappropriate antidiuresis (SIAD) caused by 
interferon-alpha therapy in a patient with chronic hepatitis C virus infection, who had 
been treated with CBZ for a long time.
Case report
Twelve days after the start of interferon-alpha and ribavirin therapy, a 31-year-old man 
was admitted for investigation of hyponatremia. The patient had been given a large 
blood transfusion and had undergone bone marrow transplantation for acute leukemia 
at 17 years of age, following which he developed chronic hepatitis C virus infection. At 
the age of  25 years, CBZ (400 mg/day) treatment was begun for temporal lobe epilepsy, 
and, 1 year later, the CBZ dose was increased to 800 mg/day. At the age of  29 years, the 
patient developed deep venous thrombosis of the right leg and was treated with catheter-
directed thrombolysis using an intravenous catheter ﬁ  lter; he was then placed on warfarin 
potassium (1.5 mg/day) and bucolome (300 mg/day) orally. On August 11, 2005, the 
patient was started on interferon-alpha 2b injections (100 μg /week) subcutaneously and International Journal of General Medicine 2008:1 22
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ribavirin (800 mg/day) orally for worsening liver function; 
GOT (glutamic-oxaloacetic transaminase) was 34 IU/l, GPT 
(glutamic-pyruvic transaminase) was 63 IU/l, and hepatitis C 
virus-RNA titer was high (700 KIU/ml). Before interferon-alpha 
and ribavirin therapy were started, blood electrolytes, including 
serum sodium level, had been consistently normal (Figure 1). 
The patient was not anemic, and the C-reactive protein level 
was normal. The patient complained of fatigue 7 days after 
beginning interferon-alpha 2b and ribavirin therapy; laboratory 
testing showed that he had hyponatremia (Figure 1).
The patient was 175 cm tall and weighed 71 kg. 
Temperature was normal (36.2 °C), and the blood pressure 
(94/58 mmHg) and the pulse rate (80/min) were normal in the 
recumbent position. Examination of the palpebral conjunctiva 
indicated anemia. No signs of edema, dehydration, or 
abnormal pigmentation were present. The patient was fully 
conscious. Laboratory ﬁ  ndings showed anemia and a high 
C-reactive protein level. Other tests, including interleukin 
levels, were within normal limits. A plain chest X-ray ﬁ  lm 
was normal. Computed tomography body scans and elec-
trocardiograms were normal. The intensity of the posterior 
pituitary gland was normal on T1-weighted magnetic 
resonance imaging.
Despite a hypo-osmotic hyponatremia, the patient’s 
urinary sodium concentration was higher than 20 mEq/l, and 
urine osmolality was also higher than his blood osmolality 
(Table 1). The serum uric acid was low. Thyroid, adrenal, and 
renal functions were normal, and plasma renin, aldosterone, 
and atrial natriuretic peptide (ANP) concentrations were 
normal (Table 1).
The CBZ, warfarin potassium, and bucolome could not be 
discontinued because they were all essential; in particular, of 
all the other antiepileptic regimens, only CBZ was effective 
for treating his epilepsy. Furthermore, the interferon-alpha 
2b and ribavirin treatments were considered essential to treat 
his chronic hepatitis C virus infection for one year.
The arginine vasopressin (AVP) level and the plasma 
osmolality were normalized to 6.1 pg/ml and 291 mosmol/kg, 
respectively, by administration of dimethylchlortetracycline 
(DMC) (900 mg/day) and restriction of water intake (20 ml/kg 
body weight) (Figure 1). Lithium (400 mg/day) therapy for 
one year resulted in normonatremia, with a plasma AVP 
concentration of less than 0.5 pg/ml (Figure 1); this effectively 
prevented the development of hyponatremia. Administration 
of lithium with restriction of water intake was discontinued 
one year later. Subsequently, the hyponatremia worsened 
during interferon-alpha 2b therapy (Figure 1). Two weeks 
later, the interferon-alpha 2b therapy was also stopped, 
and the hyponatremia completely recovered 6 months later 
while CBZ, warfarin potassium, and bucolome were contin-
ued (Figure 1). One year later, the blood sodium and AVP 
concentrations were 137 mEq/l and 0.7 pg/ml, respectively.
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Figure 1 Changes in serum sodium (Na) concentration (•–•) and plasma vasopressin (AVP) concentration (○…○) before and during interferon-alpha 2b therapy during 
water intake restriction with dimethylchlortetracycline (DMC) or lithium, and after their discontinuation.   The carbamazepine, warfarin potassium,  and bucolome had been 
administered for more than 2 years before hyponatremia developed and had been continued afterwards.   The stippled bar represents the normal serum Na concentration 
range, and the dotted line represents the lower limit of the normal AVP concentration range.International Journal of General Medicine 2008:1 23
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The basal AVP concentration relative to plasma osmolality 
was below the normal range in healthy subjects (Figure 1), 
and it was suppressed by 50% with water loading performed 
19 days after starting interferon-alpha 2b injections (Figure 2). 
Plasma ANP levels decreased after water loading (Figure 2). 
One year after discontinuing interferon-alpha 2b therapy, while 
still taking CBZ, warfarin potassium, and bucolome, a second 
water-loading test showed that the minimum plasma sodium 
and osmolality values obtained 4 hours after water loading were 
higher than those obtained at the time of the ﬁ  rst water-loading 
test, but they were still lower than those in healthy subjects 
(Figure 2), and they were accompanied with a nonsuppressive 
sodium concentration and osmolality in the urine.  The cumula-
tive urine volume excretion increased more than during the ﬁ  rst 
water-loading test, but it was still lower than in healthy subjects 
(Figure 2).  The baseline plasma AVP level was higher than it had 
been during the ﬁ  rst water-loading test, and it was not suppressed 
after water loading, while the plasma ANP levels at baseline and 
during water loading were normalized (Figure 2).
Discussion
CBZ-induced hyponatremia is uncommon in patients treated 
with CBZ alone (Gandelman 1994). Although the predisposing 
risk factors include age, CBZ dosage/level, and polyphar-
macy, polypharmacy is a particularly important risk factor 
(Kuz and Manssourian 2005). The present patient developed 
hyponatremia after receiving interferon-alpha 2b therapy 
while on CBZ treatment, and the hyponatremia recovered 
completely when the interferon-alpha 2b therapy was stopped. 
The laboratory data indicate that the hyponatremia was not 
due to adrenal insufﬁ  ciency, such as Sheehan’s syndrome, 
with interferon treatment (Mabe et al 1997), but might have 
been due to abnormal antidiuresis (Zerbe et al 1980).
The abnormal antidiuresis was conﬁ  rmed by the marked 
decrease in the cumulative urine excretion for 4 hours after 
water loading. Though it has generally been considered 
dangerous to perform the water-loading test in patients with 
hyponatremia, in the present case, no serious adverse events 
occurred during the water-loading test.
There have been many reports of hyponatremia in patients 
treated with interferon (Jones et al 1983; Bennet et al 1986; 
Lei et al 1995; Berghmans 1996; Bjorck and Samuelsson 
1996). However, the mechanism is unclear.
In healthy subjects, plasma ANP concentration increases 
as plasma volume increases (Kamoi et al 1988). Although 
patients with SIAD show various changes (Kamoi et al 
1987; Kamoi 1997), in the present case, SIAD was 
suppressed by the increase in plasma volume induced by 
water loading. Therefore, ANP secretion did not cause 
the SIAD. Another possible cause is a neoplasm (Kamoi 
et al 1987). However, in the present patient, there was no 
evidence of a neoplasm. The patient’s high C-reactive 
protein level may have caused SIAD. Although such 
hyponatremia may be caused by increased interleukin-1β 
or -6 levels (Mastorakos et al 1994; Chubachi et al 1995), 
blood levels of these cytokines were not elevated in the 
present patient. Various autoimmune diseases induced by 
interferon-alpha therapy (Conrad 2003) may cause SIAD 
due to the presence of a V2 receptor-stimulating antibody, 
such as the thyrotropin-stimulating hormone receptor-
stimulating antibody found in Grave’s disease. Alternately, 
interferon alpha may cause constitutive activation of the V2 
receptor with polymorphism, as shown when a mutation 
of the V2 receptor causes an SIADH-like clinical picture 
(Feldman et al 2005). The possibilities are unlikely because 
there are no reports in the literature.
Table 1 Endocrinological analysis during the week after admission
Blood Urine
Sodium 124 mEq/l 95 mEq/l
Osmolality 260 mosmol/kg 710 mosmol/kg
Blood
Vasopressin 0.4 pg/ml (0.5–3.1) Renin 4.3 pg/ml (2.5–21)
Aldosterone 65 pg/ml (45–106) ANP 40.5 pg/ml (0–43)
TSH 2.1 μU/ml (0.30–4.30) Antithyroglobulin antibody  0.3 U/ml (0.3)
Free T3 2.39 pg/ml (2.00–4.90) Antiperoxidase antibody 0.1 U/ml (0.1)
Free T4 0.91 ng/dl (0.70–1.80) TSH receptor antibody 1.0 IU/l (1.0)
Cortisol* 17 μg/dl (4–19) ACTH* 10.5 pg/ml (4.4–48)
Interleukin-1β 0.125 pg/ml (0.125) Interleukin-6 1.92 pg/ml (0.22–4.62)
Notes: *Sampled at 8 AM.   ANP; atrial natriuretic hormone.International Journal of General Medicine 2008:1 24
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Figure 2 Changes in blood and urine sodium concentrations and osmolality, and in plasma atrial natriuretic hormone (ANP) and vasopressin (AVP) levels, and cumulative urine 
volume with water loading (20 ml/kg) 19 days after beginning interferon-alpha 2b therapy while continuing carbamazepine, warfarin, and bucolome, (•–•) and the corresponding 
changes (○…○) during repeated water loading one year after discontinuation of interferon-alpha 2b therapy. Each stippled area represents the normal range.
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The most likely cause of the hyponatremia in the present 
case was that interferon therapy may have reinforced a direct 
or indirect pharmacological effect of other drugs on the renal 
tubules. To the best of our knowledge, hyponatremia caused 
by administration of warfarin with bucolome or ribavirin 
alone has not been reported in the literature. Also, interferon 
therapy alone has not been demonstrated to cause SIAD. Most 
patients appear to develop SIAD in combination with other 
drugs (Jones et al 1983; Bennet et al 1986; Lei et al 1995; 
Berghmans 1996; Bjorck and Samuelsson 1996). In fact, CBZ 
is known to sensitize the renal distal tubules (Meinders et al 
1974; Wales 1975; Stephens et al 1978) or to cause inap-
propriate secretion of AVP (Soelberg Sørensen and Hammer 
1984), thus, CBZ could have caused the abnormal antidiuresis 
in the present case. In addition, hyponatremia has been 
shown to improve following withdrawal of CBZ (Inamura 
et al 1999). However, in the present case, CBZ could not be 
stopped because it was essential. In addition, the possibility 
that CBZ causes hyponatremia is supported by the observation 
that lithium therapy and DMC are useful to treat it (Vieweg 
et al 1987), although lithium and CBZ in combination have 
been reported to be neurotoxic. It should be emphasized that 
prescribing these medications together should be done with 
caution. In the present case, CBZ therapy alone did not cause 
hyponatremia, and the combination of CNZ and interferon 
therapy may have caused the hyponatremia. This ﬁ  nding sup-
ports the hypothesis that interferon-alpha 2b is a predisposing 
risk factor for CBZ-induced hyponatremia. Although the 
factors associated with an increased risk for CBZ-induced 
hyponatremia are less well understood (Kuz and Manssourian 
2005), interferon therapy should be considered a predisposing 
risk factor. Although CBZ levels were not drawn before and 
after the introduction of interferon alpha in any of the reported 
cases, CBZ blood levels would have helped establish CBZ 
as a predisposing risk factor.
In conclusion, we report the case of a young man who 
developed SIAD following interferon-alpha 2b therapy for 
chronic hepatitis C virus. The SIAD may have been caused 
by sensitizing substances that may have enhanced the direct 
or indirect pharmacological effects of interferon-alpha on 
the renal distal tubules. Patients on CBZ therapy should be 
observed carefully for the development of hyponatremia 
when they are started on interferon-alpha 2b therapy.
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